BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2528892)

  • 1. Pituitary-ovarian activity when switching from various monophasic pills to a triphasic pill.
    Eyong E; Priddy AR; Killick SR; Elstein M
    Adv Contracept; 1989 Mar; 5(1):1-11. PubMed ID: 2528892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
    Rossmanith WG; Steffens D; Schramm G
    Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory criteria for menopause in women using oral contraceptives.
    Creinin MD
    Fertil Steril; 1996 Jul; 66(1):101-4. PubMed ID: 8752618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of follicular growth and luteal function of "missing the pill". A comparison between a monophasic and a triphasic combined oral contraceptive.
    Landgren BM; Csemiczky G
    Contraception; 1991 Feb; 43(2):149-59. PubMed ID: 1828225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
    van Heusden AM; Fauser BC
    Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pulsatile luteinizing hormone patterns in long term oral contraceptive users.
    Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
    J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel.
    Gaspard UJ; Romus MA; Gillain D; Duvivier J; Demey-Ponsart E; Franchimont P
    Contraception; 1983 Jun; 27(6):577-90. PubMed ID: 6225622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum gonadotropin and ovarian steroid levels in women during administration of a norethindrone-ethinylestradiol triphasic oral contraceptive.
    Ling WY; Johnston DW; Lea RH; Bent AE; Scott JZ; Toews MR
    Contraception; 1985 Oct; 32(4):367-75. PubMed ID: 3935373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pituitary and ovarian function in women receiving hormonal contraception.
    Cohen BL; Katz M
    Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shorter pill-free interval in combined oral contraceptives decreases follicular development.
    Spona J; Elstein M; Feichtinger W; Sullivan H; Lüdicke F; Müller U; Düsterberg B
    Contraception; 1996 Aug; 54(2):71-7. PubMed ID: 8842582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further studies on pituitary and ovarian function in women receiving hormonal contraception.
    Cohen BL; Katz M
    Contraception; 1981 Aug; 24(2):159-72. PubMed ID: 6794980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FSH and ovarian response: spontaneous recovery of pituitary-ovarian activity during the pill-free period vs. exogenous recombinant FSH during high-dose combined oral contraceptives.
    van Heusden AM; Coelingh Bennink HJ; Fauser BC
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):509-17. PubMed ID: 11966744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel.
    Gaspard UJ; Dubois M; Gillain D; Franchimont P; Duvivier J
    Contraception; 1984 Apr; 29(4):305-18. PubMed ID: 6430638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment.
    Elomaa K; Lähteenmäki P
    Contraception; 1999 Nov; 60(5):275-9. PubMed ID: 10717779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K; Lunell NO; Zador G
    Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
    Prasad RN; Liew D; Ratnam SS
    Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.